Stocky turns companies like Bruker Corporation into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Avoid. Broker's 22.4 Growth Compounder Score reflects anemic revenue growth insufficient to justify a 28× forward P/E, while its 12 Value Compounder Score signals no margin of safety. Material revenue exposure to cyclical U.S. academic/NIH funding and Chinese government stimulus creates structural headwinds that offset the company's modest 63.3 Leadership Alignment score.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Bruker Corporation:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 28/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Bruker Corporation (BRKR) at 28/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. Broker's 22.4 Growth Compounder Score reflects anemic revenue growth insufficient to justify a 28× forward P/E, while its 12 Value Compounder Score signals no margin of safety. Material revenue exposure to cyclical U.S. academic/
BRKR's current Stocky Verdict is 28/100, placing it in the "Avoid" band. This composite combines a 22/100 Compounder score, 63/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Bruker Corporation yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Bruker Corporation scores 63/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Bruker Corporation's Vulnerability Profile scores 25/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Bruker Corporation.
Sign up free and unlock the full analysis on BRKR — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for BRKR in the app.
